ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VRS Versarien Plc

0.1225
-0.004 (-3.16%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Versarien Plc LSE:VRS London Ordinary Share GB00B8YZTJ80 ORD 0.01P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.004 -3.16% 0.1225 0.117 0.1275 0.1295 0.1105 0.1225 30,077,124 16:35:17
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Chemicals & Chem Preps, Nec 11.64M -8.07M -0.0244 -0.05 430.01k

Versarien PLC Preliminary Results (6260H)

05/08/2021 7:00am

UK Regulatory


Versarien (LSE:VRS)
Historical Stock Chart


From Mar 2021 to Mar 2024

Click Here for more Versarien Charts.

TIDMVRS

RNS Number : 6260H

Versarien PLC

05 August 2021

5 August 2021

Versarien Plc

("Versarien" or the "Company" or the "Group")

Preliminary Results for the year ended 31 March 2021

Versarien Plc (AIM:VRS), the advanced engineering materials group, is pleased to announce its unaudited results for the year ended 31 March 2021.

Operational highlights

-- Acquisition of chemical vapour deposition graphene assets and IP from Hanwha Aerospace Company Limited, South Korea, for a consideration of 11 million ordinary shares in Versarien valued at GBP4.34 million

-- Awarded GBP5 million Innovate UK loan with GBP2.26 million received during the year for the Company's GSCALE project (an acronym for Graphene, Seat, Concrete, Arch, Leisure, Elastomer)

-- Awarded a GBP1.95 million development agreement by the Defence, Science and Technology Laboratory ("DSTL"), a part of the Ministry of Defence

-- Award of EU Grant of EUR357,000 to Gnanomat for scale-up and development of electrode materials

-- Launch of graphene enhanced protective face masks utilising Polygrene(TM) , Versarien's graphene enhanced polymer

-- Project completed with Rolls Royce and the Graphene Engineering Innovation Centre to understand and create technological advances in the aerospace sector utilising chemical vapour deposition (CVD) graphene and other 2D materials

   --     Formation of the Versarien Graphene Advisory Panel ("VGAP") 

-- Board strengthened by the appointment of James Stewart CBE as the Company's new independent Non-executive Chairman

   --     Appointment of Dr. Stephen Hodge to the Company's Board as Chief Technology Officer 

Financial highlights

   --     Group revenues of GBP6.6 million (2020: GBP8.3 million) 
   --     Adjusted LBITDA* of GBP1.8 million (2020: GBP1.6 million) 

-- Reported loss before tax of GBP8.1 million (2020: GBP4.7 million) after a non-cash share based payments charge in the year of GBP1.2 million (2020: GBP1.2 million) and a non-cash GBP3.3 million charge arising from a reduction in the IFRS 13 valuation of the Lanstead Sharing Agreement (2020: GBP1.0 million gain)

   --     Cash at 31 March 2021 of GBP2.4 million (31 March 2020: GBP1.7 million) 

-- Issue of 8.75 million ordinary shares re-invested into an 18-month sharing agreement with Lanstead Capital Investors LP ("Lanstead"), a US headquartered institutional investor

   --     Net assets of GBP16.5 million at 31 March 2021 (31 March 2020: GBP15.7 million) 

*Adjusted LBITDA (Loss before, interest, tax, depreciation and amortisation) excludes exceptional items, other gains/losses and share based payment charges

Post Period highlights

-- GBP1.93 million strategic investment in Versarien by Graphene Lab Limited including 5% royalty agreement and 2% trademark agreement on sales

-- Acquisition of Spanish graphene manufacturing assets to provide up to an additional 100 tonne powder capacity per annum

-- Orders placed for the purchase of ink scale up equipment to give up to an additional 12,000 litres of ink capacity per annum

   --      Lease signed on new dedicated graphene production facility in Longhope, Gloucestershire 

-- Textile supply agreement signed with Crosslete and discussions ongoing with multiple garment suppliers

-- Agreement signed with one of the world's largest packaging companies to evaluate graphene-based coatings

Commenting, Neill Ricketts, Chief Executive Officer of Versarien, said:

"Despite the challenges arising from the pandemic, which not unexpectedly impacted our mature businesses, we have continued to focus on the commercialisation of our graphene technologies and in particular through the GSCALE project. I am pleased to report that the manufacturing scale up is advancing in tandem with the progress on commercialisation of the project's applications.

Highlights include the development and supply agreements for textiles and the number of infrastructure opportunities following the successful pourings of graphene enhanced concrete. In addition, we are working with multiple industrial partners to develop composite structures for automotive, aerospace, defence and rail. We have also demonstrated 40% improvement in concrete strength, 30% increase in tyre rubber stiffness and have applied to trademark GrapheneWear(TM) as part of the textile commercialisation. With this we continue to pursue our strategy of global positioning to ensure that our products can be supplied to multiple sectors in multiple markets."

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN

For further information please contact:

 
Versarien 
 Neill Ricketts, CEO 
 Chris Leigh, CFO                               +44 (0)1242 269 122 
SP Angel Corporate Finance (Nominated Adviser 
 and Joint Broker) 
 Matthew Johnson, Ewan Leggat, Adam Cowl        +44 (0)20 3470 0470 
                                                ------------------- 
Berenberg (Joint Broker) 
 Mark Whitmore, Ciaran Walsh                    +44 (0)20 3207 7800 
                                                ------------------- 
Yellow Jersey (Investor Relations) 
 Charles Goodwin 
 Henry Wilkinson 
 Versarien@yellowjerseypr.com                   +44 (0)20 3004 9512 
                                                ------------------- 
 

Notes to Editors:

About Versarien

Versarien Plc ( AIM:VRS ), is an advanced engineering materials group. Leveraging proprietary technology, the Group creates innovative engineering solutions for its clients in a diverse range of industries.

For further information please see: http://www.versarien.com

Chairman's Statement

Despite the challenges presented by the Covid-19 pandemic, I am pleased to report that the Company has continued apace with its strategy to commercialise its graphene technologies and expand its portfolio of graphene products. In doing so, it is supported by the UK Government through the Innovate UK loan of GBP5 million and the GBP1.9 million development contract from DSTL as well as through the continued support of Lanstead.

In December 2020, we expanded our product portfolio with the acquisition of chemical vapour deposition ("CVD") assets and IP from Hanwha Aerospace Company Limited ("Hanwha"). The CVD plant and equipment has now been successfully transferred from Hanwha to its new premises leased by Versarien Korea Limited ("VKL"), with re-commissioning underway. We have been assisted by our South Korean partner Graphene Lab Limited ("GLL") which, as previously announced, took a 15% stake in VKL as well as subscribing GBP1.93 million of new capital to Versarien. The VKL board has also been strengthened by the appointment of three new local directors.

Significant progress has also been made with the GSCALE project, for which we have now purchased additional graphene production equipment at a cost approaching GBP1 million. Particular application highlights include the impressive results in concrete, where the mechanical properties have been improved and surface cracking reduced by using graphene additive, and in textiles, where development and supply agreements have been signed.

The DSTL contract continues to progress well with revenues of GBP0.3 million in the year under review and a further GBP1.6 million anticipated for delivery this financial year.

I would like to thank all our staff for their continued endeavours, particularly during the pandemic, without which we would not have been able to make the progress that we have. I look forward to the Company reporting further progress during the current financial year.

James Stewart CBE

Non-executive Chairman

Chief Executive Officer's Review and Strategic Report

The acquisition of the Hanwha CVD graphene assets and patents, the setting up of VKL in South Korea and our partnership/investment from GLL continues our strategy of establishing a global platform for our technology. We now have operations in the United Kingdom, Spain and South Korea as well as a sales presence in the USA and in China. This global footprint will facilitate our commercial development as the global graphene market begins to gain traction.

We have continued to progress graphene enhanced mask sales which can only be achieved if the required standards have been met. We now have seventeen certificates and have met the following standards:

   --     GB2626-2019 (general standards) 
   --     ISO 18184:2014(E) (antiviral) 
   --     GB/T 20944.3-2008 (anti-bacterial) 
   --     GB/T 20944.2-2007 (anti-bacterial) 
   --     EN 149-2001+A1-2009 (filtering, clogging, cleaning and disinfecting) 

In addition, our masks have been independently tested and proven not to emit graphene particles which will enable us to register them as nano-safe masks.

The following sections describe the activities of the business in accordance with the segmental analysis adopted since 2017. Since the year end, the Board has approved the leasing of new dedicated graphene manufacturing facilities in Longhope, Gloucestershire, which will house the recently acquired Spanish plant and equipment, the new ink production equipment and the existing graphene production equipment currently located in Cheltenham. The continued focus on graphene means that the non-core aluminium operations of Versarien Technologies Limited are being wound down and in future the segmental analysis will be split between technology businesses and mature businesses.

GRAPHENE AND PLASTIC PRODUCTS

Domestic Graphene

The UK operations are centred around the GSCALE project funded by the GBP5 million Innovate UK loan and I am pleased to summarise the significant progress during the year and subsequently in each of the work packages:

Work Package G (Graphene)

The objective is to scale production of high-quality graphene to greater than 10 tonnes per annum to meet the expected demand from the projects described below. Our key partners include graphite producers and miners, chemical suppliers and equipment manufacturers incorporating recycling and reuse as an environmentally friendly and economic production process.

Post period end, we have purchased two large scale systems for ink production and ancillary equipment at a cost of GBP342,000, which will increase ink production capacity from up to 3,000 litres per annum to up to 15,000 litres per annum, depending on formulation.

In addition, we have purchased the graphene manufacturing assets (including control systems, laboratory test equipment and graphene process IP) used by a former competitor in Spain at a cost of EUR600,000 which will be used to manufacture graphene that can be used, amongst other applications, in energy storage devices and elastomers. This will give a capacity of up to 100 tonnes of graphene per annum when fully commissioned and developed.

These assets will be located in a new dedicated 14,000 square foot facility in Longhope, Gloucestershire, together with the existing graphene production equipment currently in Cheltenham, where the lease ends in September 2021.

Work Package S (Seat)

The Seat package grew from previous developments of lighter, flame-retardant seat backs for the aerospace industry involving the dispersion of graphene in various thermoset systems used in fibre reinforced polymer composites.

We have now extended this to also include rail products, including interior applications and door panels. Automotive opportunities in this field are expanding too with the growth of electric vehicles requiring structural light weighting to enable increased range performance.

Batch size increases have required the design and procurement of resin dispersal scale up equipment, including the purchase of a large processing vessel that will take our current graphene/resin dispersion from five litres per day to up to 100 litres per day.

A rail seat back mould tool has been procured, manufactured and delivered to 2-DTech at The University of Manchester's Graphene Engineering Innovation Centre ("GEIC") for trials to develop our product and to be made available to the industry for their trials and testing requirements including mechanical and fire/smoke tests.

Work Package C (Concrete)

The Concrete workstream principally focuses on the reduction of construction CO(2) emissions, with government programmes requiring a plan for net zero carbon by 2050. Graphene can help drive efficiency (i.e. enabling faster, cheaper solutions) and increase asset life through reduced micro-cracking, low permeability and less ferrous rebar corrosion.

We are in advanced discussions with large infrastructure contractors for new rail, road and water applications with projects and trials / demonstrators being planned or already being built.

Trials with a traditional CEM1 concrete mix and the addition of Versarien's graphene show the following (all tests have been undertaken by an independent test house):

   --       Improved compression strength (+38%) 
   --       Improved flexural strength (>14% - 45%) 
   --       Increased split tensile strength (>15%) 
   --       Improved water permeability (> 200% - 0mm to 2mm) 
   --       Faster curing without micro-cracking 
   --       Increased corrosion resistance 

Further trials with an international 'readymix' concrete manufacturer have developed a graphene enhanced, low carbon, pumpable, commercial mix as typically available at any UK readymix site. This graphene enhanced concrete produced similar performance results as the CEM1 by utilising a fraction of a percent of graphene in the concrete.

Our chosen development product for the construction industry is based on our Graphinks(TM) products. This is an easy to use (simply add with the water) product, with excellent mixing results, offering workability and performance using the construction industry's regular admixture control systems.

With regards to additive manufactured concrete printing, we are progressing the purchase of a GBP250,000 robot printing system that will produce graphene enhanced 3D printed structures with a reach of 3 metres in every direction and up to 5 metres high. A significant rail infrastructure project is already engaged in discussions with a view to Versarien's technology resolving current challenges in their programme. The robot printing allows complex structures to be printed in situ and in open or confined spaces near live railway lines without the need to close the line. The potential benefits to the project include improved operator safety (as the robot can print remotely from its operator), less 'live line' downtime (trains can keep running) and efficient and economic delivery of enhanced concrete structures in the rail environment. Similar opportunities are recognised across the road and water sectors too with projects being planned.

Work Package A (Arch)

The Arch workstream covers all of our thermoplastic development and commercial exploitation through enhanced graphene characteristics across:

   --       Consumer and commodity thermoplastics; 
   --       Engineering polymers; and 
   --       Speciality plastics 

Development under these three themes include:

-- Polyolefin compounds and masterbatches being developed for extrusion moulded products (joint development agreement with a global consumer product company).

-- Graphene enhanced thermoplastic polyurethane (TPU), nylon PA12, cellulose acetate, and polycarbonate trials performed and prototypes developed for use in future ranges of eyewear frames and lenses for an eyewear manufacturer - strengths can be improved by 30% enabling longer life products.

-- Particular focus on the use of graphene to enhance recycled polymer products in such a way that the mechanical performance of the 100% recycled product is equal to a virgin polymer, thus breaking the need for addition of climate challenging oil based raw materials.

-- Biopolymers - AAC Cyroma will supply an initial batch of portable suction devices for clearing blocked airways in emergency and chronic health conditions which has the potential to make current technology obsolete. This will be manufactured from bio-derived nylon polymer.

Work Package L (Leisure)

The Leisure workstream surrounds the use of graphene inks and graphene nanoplatelets, primarily within the textile sector. Our R&D work gives attention to three distinct processes; print, coat and blend, where we have key industry partners including MAS Holdings and Coats Plc.

The print process, which utilises Graphinks(TM) , has now been scaled to pilot level production and this has allowed us to develop commercial discussions with both new parties and collaboration partners. Along with our key industry partners, we have been able to offer those customers a new range of active wear garments in men's and women's designs, which will see the benefits of thermal regulation, wicking, drying and water repellence given to wearers.

Currently we have sample garments with a number of well-known active wear brands around the world and have signed a supply agreement with Canadian boutique active wear brand Crosslete, who will introduce a new line of men's and women's garments featuring the print technology. We expect to make further announcements in this area in due course taking into consideration new product seasonal launches, commercial confidentiality and covid recovery plans of global supply chains.

The benefits of the print technology were underpinned by extensive industry testing carried out by BGGT Ltd./Shirley Technologies Ltd., a leader in its field, whereby tests were carried out in accordance with industry standard test protocols including BSENISO/BSEN/BS/AATCC methods.

In addition to this, the Company is currently collaborating with the University of Gloucestershire, which involves a number of athletes and focuses on elite performance and how the print technology can be optimised for elite level participation.

Work Package E (Elastomers)

Elastomers aims to develop large-scale graphene enhanced elastomer masterbatches for two key sectors, oil and gas and automotive tyres, but is applicable to other sectors, in particular shoes . Lab scale tests are showing good results and we are creating a solid foundation of knowledge on which to build our future business ventures in Elastomers.

The impact of the Covid-19 pandemic has seen R&D in this sector scaled back, however, our project continues if somewhat delayed. We have seen really good improvements over control rubber samples at the bench scale and having agreed a pricing structure we are expecting to move to large-scale trials in Q3 2021.

The objective for rubber formulation in tyres is to reduce rolling resistance while not sacrificing grip or wear resistance. We believe that graphene has an important part to play in achieving this. Ongoing tests have made great strides toward this, but increasing wear resistance is more complex. However, in the last set of tests conducted we saw a slightly more than three-fold reduction in wear compared to the best of the other samples tested.

We have undertaken benchmark testing of shoe competitor products in order to place our results into context. Of note is a 33% reduction in wear in a graphene outer sole formulation under development compared to a leading brand of graphene footwear. We are also seeing good improvements in mechanical properties across the board. Following increased demand masterbatches have been distributed globally in order to facilitate manufacturer testing and small-scale production trials.

With every test that is undertaken we gain further valuable information on how our products interact with elastomeric compounds. Good solid progress has been made, interest in graphene enhanced elastomers is increasing and we are moving closer to bringing products to market which we will do so on a foundation of solid scientific understanding.

Overseas Graphene

Versarien's stated strategy is to expand globally and I am pleased to report on our further progress.

Versarien Korea Limited ("VKL")

The year under review saw success with regards to acquisition and expansion into South Korea. The chemical vapour deposition equipment and IP acquisition from Hanwha (originally Samsung's technology) means that the Group now has added another important graphene manufacturing capability within the overall portfolio; whilst the setting up of a new graphene production and R&D facility in South Korea in conjunction with a CVD expert partner allows Versarien to exploit one of the largest markets for electronics and technology in the world.

The move to the new R&D facility was completed in June 2021 and we are now in the process of utility set-up and commissioning in order to produce our first CVD graphene samples and optimise the product quality.

The main focus of business in the short term will be to provide a turnkey CVD graphene production solution, securing or participating in government and other institutional projects, and developing various optical and electronic applications.

Versarien Graphene Inc. ("VGI")

VGI is making good progress in the US market although it has been slowed by the pandemic. Long term relationships have been established with a number of large players including one of the world's largest paints and coatings companies which has completed the first stage 1000-hour anti-corrosion salt spray trials with promising results using graphene as a substitute for zinc. That company is now working on multiple projects with Versarien and we are optimistic that the graphene will perform similarly in enhancing them.

Gnanomat ("GNA")

In the year under review GNA expanded the scope of its nanomaterial applications whilst still concentrating on energy storage, where excellent performance was seen when their materials were integrated in electrodes of asymmetric pseudo capacitors.

The catalytic properties of GNA's materials were also optimised and tested in other applications, such as secondary metal-air batteries, with very good results in charge, discharge and stability. Findings in this application are currently in the process of intellectual property protection. Work is also ongoing in other energy storage applications such as fuel cells.

The versatility of the technology and the synergies within Versarien allows GNA products to be used in other new potential applications such as providing antiviral effects against SARS-CoV-2 and electromagnetic interference shielding.

GNA was awarded a grant of EUR357,000 from EU funding for the INN-PRESSME project in collaboration with other industrial partners. This grant will be used to upgrade Gnanomat's pilot plant and to develop new products in collaboration with its partners, as well as to accelerate the development of products to commercialisation. At present, Gnanomat has collaborations in seven different industrial applications.

Beijing Versarien Technology ("BVT")

BVT, our wholly owned subsidiary in China, is continuing to work with a Chinese supplier on the graphene enhanced face mask project. Some variants including a graphene enhanced children's mask and an FFP3 mask have also been developed.

Going forward, it is intended BVT will source more opportunities from China under the GSCALE framework agreed between Innovate UK and Versarien, whilst ensuring that Versarien's China operations are carried out fully in line with the letter and spirit of the UK's National Security and Investment Act 2021.

Future expansion plans include establishing a presence in other potentially lucrative global markets, by way of exporting, acquisitions and/or partnerships, as and when the right opportunities arise. We will also work towards growing our current international operations, which will in turn increase our own capability and reach.

Plastic Products

AAC Cyroma Limited ("AAC") has, o ver the last 12 months, remained operational throughout the Covid-19 pandemic and lockdown period supporting the NHS with the supply of hospital bed panels and visors, along with products for utility service providers.

Turnover is showing some recovery towards pre-pandemic levels with several new projects and opportunities. The focus for the current financial year for AAC is the conversion of these opportunities into new business and to further progress opportunities for supplying graphene enhanced plastic products in conjunction with the Company's new Longhope operations.

HARD WEAR AND METALLIC PRODUCTS

The focus on the opportunities afforded by graphene together with the market challenges of Covid-19 have resulted in the decision to exit the non-core aluminium business of Versarien Technologies Limited based in Cheltenham. The lease comes to an end in September 2021 and a run-off to customers is currently in progress. The company has been re-named Versarien Graphene Limited and will be used as the revenue generating entity for UK graphene sales whilst 2-DTech Limited and Cambridge Graphene Limited will continue as the UK research and development arms of the graphene business.

Total Carbide Limited is a manufacturer of tungsten carbide wear parts and sells to a global customer base covering 40 different industries producing bespoke products for a wide spread of wear applications. These range from all aspects of the oil and gas industry, through measurement tools and cutting knives to difficult complex breakthrough technology for aerospace and defence applications as well as providing nozzles for space propulsion.

Despite being a challenging year, the company won national and regional awards for its work with apprentices and young people.

Current trading and outlook

There are indications that trading is beginning to return to pre-pandemic levels in our mature businesses, but the economic environment remains uncertain and the Company remains vigilant around costs. Much more importantly, however, the graphene prospects in both the UK and abroad are extremely exciting with our transitioning from laboratory to real world demonstrators in multiple sectors including defence, automotive, aerospace and construction; in particular, interest in using our graphene in large infrastructure projects and in textiles.

We have been fortunate to extend our team with key hires in South Korea and the UK, including project managers for our key projects as we make this transition into the commercial world. I look forward to providing further updates on customer projects in due course. We now have a strong platform of licensable IP, large global commercial partners, significant support from the UK government, especially around security, and a clear path to revenue from innovative products.

Key performance indicators

As a Group we concentrate on the following financial metrics:

 
                                                             2021      2020 
                                                          GBP'000   GBP'000 
Group revenue                                               6,567     8,281 
                                                         --------  -------- 
Gross margin percentage                                       22%       24% 
                                                         --------  -------- 
Loss before interest, tax, depreciation, amortisation, 
 exceptional costs, share based charges and other 
 gains/losses                                             (1,761)   (1,633) 
                                                         --------  -------- 
Cash used by Graphene and Plastic Products                (2,544)   (2,685) 
                                                         --------  -------- 
Cash generated by Hard Wear and Metallic Products              94       608 
                                                         --------  -------- 
Cash raised/(utilised) by parent (before loans 
 to/from subsidiaries)                                      3,152     (558) 
                                                         --------  -------- 
Increase/(decrease) in cash and cash equivalents              702   (2,635) 
                                                         --------  -------- 
 

Neill Ricketts

Chief Executive Officer

Chief Technology Officer's Review

Our R&D activities expanded rapidly in the year under review following our major G-SCALE and DSTL projects, with five new members of staff joining us in Manchester, one in Cambridge, and a new team being built in Korea following the acquisition of the CVD assets. We have subsequently expanded into a second lab at the Graphene Engineering Innovation Centre in Manchester and have invested in larger scale manufacturing, processing and coating capabilities across the graphene and 2D materials businesses that will significantly help us towards product commercialisation. We have also significantly strengthened our materials portfolio and IP position as a result of acquisitions in Spain and Korea, and we continue to innovate and evaluate patents from global universities. We have also trademarked Graphenewear(TM) and Cementene(TM) for both leisure and construction products, reflecting the great strides we are making in these areas.

Our R&D team has shown incredible resilience and flexibility during the pandemic with often restricted lab access, meaning being more organised and efficient and training new members of staff remotely.

Health & Safety of graphene

The issue of safety will be raised time and again, so it is imperative that the relevant human and environmental toxicology testing be performed to assist public awareness, and that we understand the nature of exposure of any nanoparticles when graphene is manufactured and products are used.

Ultimately, these tests can only be done as part of the global community of graphene producers.

As a leader in its field, Versarien is at the forefront of graphene and related nanomaterials health and safety. To further our involvement, over the last year I have taken on additional key industry roles, including Chairman of the Graphene REACH registration committee's Technical Working Group and become a member of the Graphene Flagship's ECHA/REACH committee, with dialogue across all the relevant parties with regards to EU and global regulations.

Although graphene's ISO definition is clear, the families of few-layer, multi-layer, nanoplatelet and nanographite materials that are produced on multi-tonnage quantities is vast, and the definitions and classification of these materials will almost certainly need to change as we learn more about specific material properties, human and environmental interactions. Accreditations, such as that we hold under the Graphene Council Verified Producer Programme, will become more important as the industry progresses.

Dr Stephen Hodge

Chief Technology Officer

Chief Financial Officer's Review

The challenges of the pandemic resulted in revenue reduction of GBP1.7 million to GBP6.6 million, but only slightly increased losses of GBP0.2 million to GBP1.8 million at the Adjusted LBITDA level (losses before interest, tax, depreciation and amortisation excluding exceptional items, share based payments charges, and other gains/losses). However, with the support of the UK Government and Lanstead, the Group was able to continue its progress towards commercialisation of its graphene products and expand its product portfolio in South Korea whilst at the same time increasing its cash resources by GBP0.7 million.

Exceptional costs were GBP0.4 million (2020: GBP1.6 million) which arose mainly through cost associated with expansion into Asia, and the purchase of the Hanwha assets. The loss before tax for the year was GBP8.1 million (2020: GBP4.7 million), after share based payment charges of GBP1.2 million (2020: GBP1.2 million) and a GBP3.3 million charge arising from the reduction in the IFRS 13 valuation of the Lanstead Sharing Agreements (2020: GBP1.0 million gain).

Cash outflow from operating activities was GBP0.7 million (2020: GBP1.5 million), interest payments were GBP0.2 million (2020: GBP0.2 million), investment in development costs and equipment was GBP1.7 million (2020: GBP0.6 million) and principal lease payments were GBP1.0 million (2020: GBP0.8 million) giving total cash outflows of GBP3.6 million (2020: GBP3.1 million). These activities were financed by net funds received from the Lanstead sharing agreements/share issue of GBP2.3 million (2020: GBP(0.1) million), funds received under the CBILS of GBP0.2 million( 2020: GBPnil) and funds received under the Innovate UK loan of GBP2.3 million (2020: GBPnil), totalling GBP4.8 million (2020: GBP(0.1) million). The surplus of GBP1.2 million (2020: deficit GBP3.2 million) resulted in reduced drawings on the invoice finance facilities of GBP0.5 million (2020: GBP0.6 million increased drawings) thus increasing cash at the year-end by GBP0.7 million (2020: GBP2.6 million decrease).

As previously announced, Lanstead has subscribed for a total of 23.75 million Ordinary Shares, through two subscriptions, at an issue price of 40 pence per Ordinary Share and benchmark price of 53.33 pence per Ordinary Share and the Company entered into related sharing agreements to receive the proceeds on a pro-rata monthly basis. Further details of the Lanstead subscription in the period and the related sharing agreements are set out in the Company's announcement of 22 December 2020.

In accordance with IFRS 13, the Sharing Agreements have been valued as at 31 March 2021 using the Monte Carlo (or multiple probability simulation) pricing model which has resulted in a valuation of GBP4,728,000 (31 March 2020: GBP6,987,000). Consequently, and in accordance with IFRS 13, a loss of GBP3,280,000 (2020: GBP987,000 gain) has been accounted for as other gains/losses in the Group Statement of Comprehensive Income.

The financial results by segment are disclosed in note 2 of these preliminary results with Graphene and Plastic Products returning sales of GBP3.7 million (2020: GBP3.9 million) and reduced losses of GBP1.7 million (2020: GBP3.3 million) after capitalising an additional GBP1.3 million of development costs in the year as a result of the GSCALE focus, including commercialisation progress which now meets IFRS criteria. Graphene sales in the year, including revenues associated with the DSTL project, were GBP0.7 million (2020: GBP0.1 million).

Hard Wear and Metallic Products returned much reduced sales of GBP2.9 million (2020: GBP4.3 million) but maintained its losses at a similar level to the prior year of GBP0.3 million (2020: GBP0.3 million) as it managed its cost base and utilised the furlough scheme through the pandemic.

Group net assets at 31 March 2021 were GBP16.5 million (2020: GBP15.7 million) and at the year end the Group had cash of GBP2.4 million (31 March 2020: GBP1.7 million), with GBP0.6 million (31 March 2020: GBP1.2 million) drawn under the invoice finance facilities. As at the year end the Company had GBP0.7 million of headroom in its invoice finance facilities (2020: GBP0.3 million). Together with the Lanstead sharing agreements and the Innovate UK loan, the Directors consider this sufficient liquidity for our current activities over the coming twelve months having made certain assumptions, further details of which are described below.

Going concern

The financial statements, which are not yet audited, have been prepared on a going concern basis, which the Directors believe to be appropriate for the following reasons:

-- The Group meets its day-to-day working capital requirements through careful cash management and the use of its invoice discounting facilities;

-- As at 31 March 2021, the Group had cash balances totalling GBP2.4 million with GBP0.7 million of headroom on its invoice discounting facilities;

   --     The Group was awarded a GBP5 million loan by Innovate UK to fund certain of its activities; 

-- The Group receives monthly settlements from its sharing agreements with Lanstead, the quantum of which is dependent upon share price; and

-- Post year end, the Group received a strategic investment of GBP1.93 million from Graphene Lab, through a subscription for 4,280,000 new Ordinary Shares at an issue price of 45 pence per Ordinary Share

The Directors have prepared detailed projections of expected future cash flows for a period of twelve months from the date of issue of this preliminary statement. These show that the Group is expected to have sufficient cash available to meet its obligations as they fall due for the foreseeable future, being at least twelve months.

The continuing effects of the Covid-19 pandemic remain uncertain so consequently there remains a risk that trading performance could be below expectations. The projections also contain certain assumptions with regards to the share price and the funds that will flow under the sharing agreements with Lanstead and there is also a risk that the share price could be below expectations. Material adverse occurrences could therefore lead to a requirement to take mitigating action.

Such actions could include raising more cash via an equity placing (there is a track record of successful placings) or, in the absence of a funding round, cost reductions in the Group. The Directors' have prepared sensitised projections for these scenarios which indicate that sufficient cash reserves would exist for the foreseeable future (at least twelve months) without any additional fundraising.

Other factors that have been considered in the Directors' assessment of going concern include:

-- The expectation that the placing authority for up to 15% of the existing share capital without pre-emption rights will be renewed at the Annual General Meeting;

   --     The continuation and adequacy of bank facilities; 

-- That there are a number of mitigating actions the Group could implement, such as reducing the funds spent on development of its technologies and overheads to concentrate solely on GSCALE opportunities;

   --     The commencement of the Innovate loan repayment which commences in May 2024; and 
   --     The purchase post year end of assets through the Innovate UK loan. 

After due consideration, the Directors have concluded that there is a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future (at least twelve months). For this reason, they continue to adopt the going concern basis in preparing the consolidated financial statements.

Chris Leigh

Chief Financial Officer

Group statement of comprehensive Income (unaudited)

Year ended 31 March 2021

 
                                                               2021       2020 
                                                    Notes   GBP'000    GBP'000 
Continuing operations 
                                                    -----  --------  --------- 
Revenue                                                 2     6,567      8,281 
Cost of sales                                               (5,112)    (6,334) 
Gross profit                                                  1,455      1,947 
                                                    -----  --------  --------- 
Other operating income                                          107          5 
Other (losses)/gains                                        (3,280)        987 
Operating expenses (including exceptional items)            (6,190)    (7,487) 
Loss from operations before exceptional items               (7,467)    (2,941) 
Exceptional items                                       3     (441)    (1,607) 
                                                    -----  --------  --------- 
Loss from operations                                        (7,908)    (4,548) 
Finance costs                                                 (165)      (160) 
Finance income                                                    5          5 
                                                    -----  --------  --------- 
Loss before income tax                                      (8,068)    (4,703) 
Income tax                                                        -         49 
Loss for the year                                           (8,068)    (4,654) 
                                                    -----  --------  --------- 
 
Loss attributable to: 
- Owners of the parent company                              (7,779)    (4,148) 
- Non-controlling interest                                    (289)      (506) 
                                                    -----  --------  --------- 
                                                            (8,068)    (4,654) 
--------------------------------------------------  -----  --------  --------- 
 
Loss per share attributable to the equity holders 
 of the Company: 
                                                    -----  --------  --------- 
 
Basic and diluted loss per share                        5   (4.45)p    (2.69)p 
--------------------------------------------------  -----  --------  --------- 
 

There is no other comprehensive income for the year.

The other (losses)/gains in the year relates to the fair value assessment of the Lanstead sharing agreements at the balance sheet date.

Group statement of financial position (unaudited)

As at 31 March 2021

 
                                                                 2021      2020 
                                                      Notes   GBP'000   GBP'000 
Assets 
                                                      -----  --------  -------- 
Non-current assets 
                                                      -----  --------  -------- 
Intangible assets                                         6     9,706     4,720 
                                                      -----  --------  -------- 
Property, plant and equipment                             7     4,119     4,316 
                                                      -----  --------  -------- 
Deferred taxation                                                  25        25 
----------------------------------------------------  -----  --------  -------- 
Trade and other receivables                                       772     4,295 
                                                      -----  --------  -------- 
                                                               14,622    13,356 
                                                      -----  --------  -------- 
Current assets 
                                                      -----  --------  -------- 
Inventory                                                       1,814     2,252 
Trade and other receivables                                     6,449     4,974 
Cash and cash equivalents                                       2,359     1,657 
                                                      -----  --------  -------- 
                                                               10,622     8,883 
                                                      -----  --------  -------- 
Total assets                                                   25,244    22,239 
----------------------------------------------------  -----  --------  -------- 
Equity 
                                                      -----  --------  -------- 
Called up share capital                                   8     1,899     1,697 
                                                      -----  --------  -------- 
Share premium account                                     8    33,003    25,497 
                                                      -----  --------  -------- 
Merger reserve                                                  1,256     1,256 
                                                      -----  --------  -------- 
Share-based payment reserve                                     3,249     2,056 
----------------------------------------------------  -----  --------  -------- 
Retained losses                                              (21,625)  (13,846) 
                                                      -----  --------  -------- 
Equity attributable to owners of the parent company            17,782    16,660 
----------------------------------------------------  -----  --------  -------- 
Non-controlling interest                                      (1,288)     (999) 
                                                      -----  --------  -------- 
Total equity                                                   16,494    15,661 
                                                      -----  --------  -------- 
 
Liabilities 
                                                      -----  --------  -------- 
Non-current liabilities 
                                                      -----  --------  -------- 
Trade and other payables                                        1,222     1,192 
Deferred tax                                                       67        67 
Innovate Loan                                                   2,260         - 
----------------------------------------------------  -----  --------  -------- 
Long-term borrowings                                              356       516 
                                                      -----  --------  -------- 
                                                                3,905     1,775 
                                                      -----  --------  -------- 
Current liabilities 
                                                      -----  --------  -------- 
Trade and other payables                                        3,748     3,218 
                                                      -----  --------  -------- 
Provisions                                                        119        97 
                                                      -----  --------  -------- 
Invoice discounting advances                                      631     1,156 
----------------------------------------------------  -----  --------  -------- 
Current portion of long-term borrowings                           347       332 
                                                      -----  --------  -------- 
                                                                4,845     4,803 
                                                      -----  --------  -------- 
Total liabilities                                               8,750     6,578 
                                                      -----  --------  -------- 
Total equity and liabilities                                   25,244    22,239 
----------------------------------------------------  -----  --------  -------- 
 

Group statement of changes in equity (unaudited)

Year ended 31 March 2021

 
                                    Share            Share-based 
                          Share   premium    Merger      payment  Accumulated    Non-controlling     Total 
                        capital   account   reserve      reserve       losses           Interest    equity 
                        GBP'000   GBP'000   GBP'000      GBP'000      GBP'000            GBP'000   GBP'000 
At 1 April 2019           1,536    19,776     1,256          899      (9,698)              (493)    13,276 
                       --------  --------  --------  -----------  -----------  -----------------  -------- 
Issue of shares             161     5,721         -            -            -                  -     5,882 
                       --------  --------  --------  -----------  -----------  -----------------  -------- 
Loss for the year             -         -         -            -      (4,148)              (506)   (4,654) 
                       --------  --------  --------  -----------  -----------  -----------------  -------- 
Share-based payments          -         -         -        1,157            -                  -     1,157 
                       --------  --------  --------  -----------  -----------  -----------------  -------- 
At 31 March 2020          1,697    25,497     1,256        2,056     (13,846)              (999)    15,661 
                       --------  --------  --------  -----------  -----------  -----------------  -------- 
Issue of shares             202     7,506         -            -            -                  -     7,708 
                       --------  --------  --------  -----------  -----------  -----------------  -------- 
Loss for the year             -         -         -            -      (7,779)              (289)   (8,068) 
                       --------  --------  --------  -----------  -----------  -----------------  -------- 
Share-based payments          -         -         -        1,193            -                  -     1,193 
                       --------  --------  --------  -----------  -----------  -----------------  -------- 
At 31 March 2021          1,899    33,003     1,256        3,249     (21,625)            (1,288)    16,494 
                       --------  --------  --------  -----------  -----------  -----------------  -------- 
 

Statement of Group cash flows (unaudited)

Year ended 31 March 2021

 
 
                                                               2021        2020 
                                                   Notes    GBP'000     GBP'000 
-------------------------------------------------  -----  ---------  ---------- 
Cash flows from operating activities 
Cash used in operations                                9      (734)     (1,487) 
Net interest paid                                             (160)       (155) 
Net cash used in operating activities                         (894)     (1,642) 
-------------------------------------------------  -----  ---------  ---------- 
Cash flows from investing activities 
Capitalised development costs and purchase 
 of intangible assets                                       (1,638)       (351) 
Purchase of property, plant and equipment                      (42)       (286) 
Net cash used in investing activities                       (1,680)       (637) 
-------------------------------------------------  -----  ---------  ---------- 
Cash flows from financing activities 
Share issue (net of funds deferred per sharing 
 agreements)*                                                     -         123 
Funds received from sharing agreements                        2,479           - 
Funds received from Innovate UK                               2,260           - 
Net funds received from CBIL                                    186           - 
Share issue costs                                             (134)       (241) 
Principal payment of leases under IFRS 16                     (990)       (791) 
Invoice discounting loan (repayments)/proceeds                (525)         553 
-------------------------------------------------  -----  ---------  ---------- 
Net cash generated from/(used in) financing 
 activities                                                   3,276       (356) 
-------------------------------------------------  -----  ---------  ---------- 
Increase/(decrease) in cash and cash equivalents                702     (2,635) 
Cash and cash equivalents at beginning of 
 year                                                         1,657       4,292 
-------------------------------------------------  -----  ---------  ---------- 
Cash and cash equivalents at end of year                      2,359       1,657 
-------------------------------------------------  -----  ---------  ---------- 
 

* During the year, 8,750,000 new ordinary shares of 1 pence each were issued at a price of 40 pence per share raising gross proceeds of GBP3.5 million which were pledged via a sharing agreement entitling the Company to receive back those proceeds over a period of 18 months adjusted for the benchmark share price.

Notes to the Financial Statements (unaudited)

1. Basis of preparation

The consolidated financial statements consolidate the results of the Company and its subsidiaries (together referred to as the "Group").

The financial information included in this preliminary announcement does not constitute statutory accounts of the Group for the years ended 31 March 2021 or 31 March 2020. The financial information for the year ended 31 March 2020 is derived from statutory accounts upon which the auditors have reported. Their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006. The auditors work on the statutory accounts of the Group for the year ended 31 March 2021 is not yet complete.

The Group financial statements have been prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006. The "requirements of the Companies Act 2006" here means accounts being prepared in accordance with "international accounting standards" as defined in section 474(1) of that Act, as it applied immediately before Implementation Period ('IP') completion day (end of transition period), including where the Group also makes use of standards which have been adopted for use within the United Kingdom in accordance with regulation 1(5) of the International Accounting Standards and European Public Limited Liability Company (Amendment etc.) (EU Exit) Regulations 2019.

2. Segmental reporting

At 31 March 2021 the Group was organised into two business segments. Central costs are reported separately.

Information reported to the Group's Chief Executive Officer for the purposes of resource allocation and assessment of performance is focused on the two principal business segments of Graphene and Plastic Products and Hard Wear and Metallic Products and, accordingly, the Group's reportable segments under IFRS 8 are based on these activities.

Segment profit/(loss) represents the profit/(loss) earned by each segment, including a share of central administration costs, which are allocated on the basis of actual use or pro rata to sales. This is the measure reported to the Chief Executive Officer for the purposes of resource allocation and assessment of segment performance. The non-core aluminium operations of Versarien Technologies Limited are being wound down and consequently in future reporting periods the segmental analysis will be split between technology businesses and mature businesses.

The segment analysis for the period ended 31 March 2021 is as follows:

 
                                          Graphene       Hard Wear 
                                       and Plastic    and Metallic   Intra-group 
                             Central      Products        Products   adjustments     Total 
                             GBP'000       GBP'000         GBP'000       GBP'000   GBP'000 
--------------------------  --------  ------------  --------------  ------------  -------- 
Revenue                            -         3,697           2,870             -     6,567 
--------------------------  --------  ------------  --------------  ------------  -------- 
Gross profit                       -           877             578             -     1,455 
Other operating income             -           103               4             -       107 
Other losses                 (3,280)             -               -             -   (3,280) 
Operating expenses           (2,686)       (2,646)           (826)          (32)   (6,190) 
Loss from operations         (5,966)       (1,666)           (244)          (32)   (7,908) 
Finance income/(charge)         (44)          (73)            (43)             -     (160) 
--------------------------  --------  ------------  --------------  ------------  -------- 
Loss before tax              (6,010)       (1,739)           (287)          (32)   (8,068) 
--------------------------  --------  ------------  --------------  ------------  -------- 
Total assets                  26,254         7,498           4,882      (13,390)    25,244 
Total liabilities            (4,074)      (13,171)         (4,413)        12,908   (8,750) 
--------------------------  --------  ------------  --------------  ------------  -------- 
Net assets/(liabilities)      22,180       (5,673)             469         (482)    16,494 
--------------------------  --------  ------------  --------------  ------------  -------- 
Capital expenditure            4,388         1,634               -             -     6,022 
Depreciation/amortisation 
 and impairment                  169           599             438            27     1,233 
--------------------------  --------  ------------  --------------  ------------  -------- 
 

The segment analysis for the period ended 31 March 2020 is as follows:

 
 
                                          Graphene       Hard Wear 
                                       and Plastic    And Metallic   Intra-group 
                             Central      Products        Products   adjustments     Total 
                             GBP'000       GBP'000         GBP'000       GBP'000   GBP'000 
--------------------------  --------  ------------  --------------  ------------  -------- 
Revenue                            -         3,942           4,342           (3)     8,281 
--------------------------  --------  ------------  --------------  ------------  -------- 
Gross profit                       -           727           1,220             -     1,947 
Other operating income             -             -               5             -         5 
Other gains                      987             -               -             -       987 
Operating expenses           (2,032)       (3,449)         (1,126)           (4)   (6,611) 
Impairment of goodwill             -         (522)           (354)             -     (876) 
--------------------------  --------  ------------  --------------  ------------  -------- 
(Loss) from operations       (1,045)       (3,244)           (255)           (4)   (4,548) 
Finance income/(charge)          (1)          (97)            (57)             -     (155) 
--------------------------  --------  ------------  --------------  ------------  -------- 
(Loss)/profit before tax     (1,046)       (3,341)           (312)           (4)   (4,703) 
--------------------------  --------  ------------  --------------  ------------  -------- 
Total assets                  21,917         6,906           5,509      (12,093)    22,239 
Total liabilities            (1,523)      (11,090)         (4,753)        10,788   (6,578) 
--------------------------  --------  ------------  --------------  ------------  -------- 
Net assets/(liabilities)      20,394       (4,184)             756       (1,305)    15,661 
--------------------------  --------  ------------  --------------  ------------  -------- 
Capital expenditure               34           324             279             -       637 
Depreciation/amortisation         23           628             458            29     1,138 
--------------------------  --------  ------------  --------------  ------------  -------- 
 

Geographical information

The Group's revenue from external customers and information about its segment assets by geographical location are detailed below:

 
                  Revenue from external 
                        customers          Non-current assets 
                        2021        2020       2021       2020 
                     GBP'000     GBP'000    GBP'000    GBP'000 
                 -----------              --------- 
United Kingdom         5,705       6,920      8,296     11,040 
                 -----------  ----------  ---------  --------- 
Rest of Europe           495         831      2,300      2,316 
                 -----------  ----------  ---------  --------- 
North America              5         273          -          - 
Other                    362         257      4,026          - 
                       6,567       8,281     14,622     13,356 
---------------  -----------  ----------  ---------  --------- 
 

3. Exceptional items

 
                                                           2021      2020 
                                                        GBP'000   GBP'000 
Relocation and restructuring costs                           53       139 
Costs relating to expansion in Asia                         137       531 
Acquisition costs                                           186        32 
Impairment of goodwill relating to subsidiaries (see 
 note 6)                                                      -       876 
Other                                                        65        29 
                                                       --------  -------- 
                                                            441     1,607 
-----------------------------------------------------  --------  -------- 
 

4. Dividends

As stated in the Company's AIM Admission Document, the Board will not be declaring or proposing any dividends until such time as the commercialisation of its product portfolio has generated sufficient distributable reserves from which to do so.

5. Loss per ordinary share

The calculation of the basic loss per share for the period ended 31 March 2021 and 31 March 2020 is based on the losses attributable to the shareholders of Versarien Plc divided by the weighted average number of shares in issue during the year. The calculation of diluted loss per share is based on the basic loss per share adjusted to allow for the issue of shares on the assumed conversion of all dilutive options. However, in accordance with IAS 33 "Earnings Per Share" potential ordinary shares are only considered dilutive when their conversion would decrease the profit per share or increase the loss per share. As at 31 March 2021 there were 14,677,130 (2020: 14,677,130) potential ordinary shares which have been disregarded in the calculation of diluted loss per share as they were considered non-dilutive at that date.

 
                                    Loss    Weighted 
                            attributable     average 
                                      to   number of  Basic loss 
                            shareholders      shares   per share 
                                 GBP'000     GBP'000       pence 
Year ended 31 March 2021         (7,779)     174,660      (4.45) 
                           -------------  ----------  ---------- 
Year ended 31 March 2020         (4,148)     153,956      (2.69) 
                           -------------  ----------  ---------- 
 

6. Intangible assets

 
                                                           Other 
                                          Goodwill   intangibles          Total 
                                           GBP'000       GBP'000        GBP'000 
Cost 
                                          --------  ------------  ------------- 
At 1 April 2019                              4,431         1,976          6,407 
                                          --------  ------------  ------------- 
Additions                                        -           351            351 
At 31 March 2020                             4,431         2,327          6,758 
Additions                                        -         5,138          5,138 
At 31 March 2021                             4,431         7,465         11,896 
----------------------------------------  --------  ------------  ------------- 
Accumulated amortisation and impairment 
                                          --------  ------------  ------------- 
At 1 April 2019                                  -         1,089          1,089 
Amortisation charge                              -            73             73 
Impairment                                     876             -            876 
At 31 March 2020                               876         1,162          2,038 
Amortisation charge                              -           152            152 
At 31 March 2021                               876         1,314          2,190 
----------------------------------------  --------  ------------  ------------- 
Carrying value 
At 31 March 2021                             3,555         6,151          9,706 
----------------------------------------  --------  ------------  ------------- 
At 31 March 2020                             3,555         1,165          4,720 
                                          --------  ------------  ------------- 
 

Other intangible assets

 
                                     31 March 2021  31 March 2020 
                                           GBP'000        GBP'000 
Customer relationships/order books              27             54 
                                     -------------  ------------- 
Development costs                            2,453            901 
Licence                                         58             28 
Intellectual property                        3,613            182 
Total                                        6,151          1,165 
-----------------------------------  -------------  ------------- 
 
   7.            Property, plant and equipment 
 
                              ROU asset   Plant and      Leasehold 
                                          equipment   improvements   Total 
Group                                       GBP'000        GBP'000   GBP'000 
Cost 
                              ---------  ----------  -------------  -------- 
At 1 April 2019                       -       9,862            518    10,380 
                              ---------  ----------  -------------  -------- 
Adjustment on transition to 
 IFRS 16                          6,377     (4,453)              -     1,924 
                              ---------  ----------  -------------  -------- 
Additions                           160         127              -       287 
----------------------------  ---------  ----------  -------------  -------- 
Disposals                             -       (132)              -     (132) 
                              ---------  ----------  -------------  -------- 
At 31 March 2020                  6,537       5,404            518    12,459 
                              ---------  ----------  -------------  -------- 
Additions                             -         884              -       884 
At 31 March 2021                  6,537       6,288            518    13,343 
----------------------------  ---------  ----------  -------------  -------- 
Accumulated depreciation 
                              ---------  ----------  -------------  -------- 
At 1 April 2019                       -       7,126             84     7,210 
                              ---------  ----------  -------------  -------- 
Adjustment on transition to 
 IFRS 16                          2,567     (2,567)              -         - 
Charge for the year                 820         218             27     1,065 
Disposals                             -       (132)              -     (132) 
At 31 March 2020                  3,387       4,645            111     8,143 
Charge for the year                 812         172             24     1,008 
----------------------------  ---------  ----------  -------------  -------- 
Impairment                            -          73              -        73 
                              ---------  ----------  -------------  -------- 
At 31 March 2021                  4,199       4,890            135     9,224 
----------------------------  ---------  ----------  -------------  -------- 
Net book value 
At 31 March 2021                  2,338       1,398            383     4,119 
----------------------------  ---------  ----------  -------------  -------- 
At 31 March 2020                  3,150         759            407     4,316 
                              ---------  ----------  -------------  -------- 
 

Under IFRS16 the Right of Use assets for the Group are as follows:

 
                                        Group 2021                             Group 2020 
                                          GBP'000                                GBP'000 
                           Plant & Equipment  Buildings    Total  Plant & Equipment  Buildings    Total 
                           -----------------  ---------  -------  -----------------  ---------  ------- 
Cost                                   4,613      1,924    6,537              4,613      1,924    6,537 
                           -----------------  ---------  -------  -----------------  ---------  ------- 
Accumulated depreciation             (3,001)    (1,198)  (4,199)            (2,788)      (599)  (3,387) 
                           -----------------  ---------  -------  -----------------  ---------  ------- 
Net book value                         1,612        726    2,338              1,825      1,325    3,150 
                           -----------------  ---------  -------  -----------------  ---------  ------- 
 

8. Called up share capital and share premium

 
                       Number  Ordinary     Share 
                    of shares    shares   premium     Total 
                         '000   GBP'000   GBP'000   GBP'000 
At 1 April 2019       153,624     1,536    19,776    21,312 
                   ----------  --------  --------  -------- 
Issue of shares        16,058       161     5,721     5,882 
At 31 March 2020      169,682     1,697    25,497    27,194 
Issue of shares        20,188       202     7,506     7,708 
At 31 March 2021      189,870     1,899    33,003    34,902 
-----------------  ----------  --------  --------  -------- 
 

During the year the Company issued:

-- 11,000,000 Ordinary shares as consideration to acquire certain graphene production related assets and intellectual property from South Korea based Hanwha Aerospace Company Limited at 39.475 pence per share; and

-- 8,750,000 Ordinary shares raising GBP3.5 million (before expenses) in an additional subscription agreement with Lanstead Capital Investors LP at 40 pence per share with 437,500 ordinary shares issued in connection with entering into the Sharing Agreement.

9. Cash used in operations

 
 
                                                            2021      2020 
                                                         GBP'000   GBP'000 
                                                        --------  -------- 
Loss before tax                                          (8,068)   (4,703) 
                                                        --------  -------- 
Adjustments for: 
                                                        --------  -------- 
  Share-based payments                                     1,193     1,157 
                                                        --------  -------- 
  Depreciation and impairment                              1,081     1,065 
                                                        --------  -------- 
  Amortisation                                               152        73 
                                                        --------  -------- 
  Impairment of Goodwill                                       -       876 
                                                        --------  -------- 
  R&D tax credit repayment                                     -        49 
                                                        --------  -------- 
  Loss or (gain) on FV movement of sharing agreements      3,280     (987) 
                                                        --------  -------- 
  Finance cost                                               160       155 
                                                        --------  -------- 
  Increase in trade and other receivables                  (211)      (35) 
                                                        --------  -------- 
  Decrease in inventories                                    438         1 
  Increase in trade and other payables                     1,241       862 
Cash flows from operating activities                       (734)   (1,487) 
------------------------------------------------------  --------  -------- 
 

10. Report and accounts

Copies of the 2021 Annual Report and Accounts will be posted to shareholders in due course once they are finalised and approved. Further copies may be obtained by contacting the Company Secretary at the registered office. In addition, the 2021 Annual Report and Accounts will be available, when published, to download from the investor relations section on the Company's website www.versarien.com .

- Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

FR SSWFULEFSEDA

(END) Dow Jones Newswires

August 05, 2021 02:00 ET (06:00 GMT)

1 Year Versarien Chart

1 Year Versarien Chart

1 Month Versarien Chart

1 Month Versarien Chart

Your Recent History

Delayed Upgrade Clock